NASDAQ
28.08.26 | 21:59
2,285 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.08. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.08. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.08. | IceCure Medical GAAP EPS of -$3.17 misses by $1.65, revenue of $1.82M beats by $0.37M | 3 | Seeking Alpha | ||
| 12.08. | IceCure Medical: IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year | 228 | PR Newswire | The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following... ► Artikel lesen | |
| 06.08. | IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment | 174 | PR Newswire | Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval
The site will... ► Artikel lesen | |
| ICECURE MEDICAL Aktie jetzt für 0€ handeln | |||||
| 26.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.06. | What's Going On With IceCure Medical Stock On Friday? | 6 | Benzinga.com | ||
| 25.06. | IceCure Medical: IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement | 166 | PR Newswire | CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive... ► Artikel lesen | |
| 18.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.06. | IceCure Medical: IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance | 508 | PR Newswire | Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated... ► Artikel lesen | |
| 02.06. | IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance | 1 | Seeking Alpha | ||
| 02.06. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.06. | IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance | 442 | PR Newswire | Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy
CAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical... ► Artikel lesen | |
| 19.05. | IceCure Medical: IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked | 280 | PR Newswire | At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors =3 cm and... ► Artikel lesen | |
| 13.05. | IceCure Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.05. | IceCure Medical: IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement | 347 | PR Newswire | No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares
CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM)... ► Artikel lesen | |
| 12.05. | IceCure Medical GAAP EPS of $0.06, revenue of $911M | 3 | Seeking Alpha | ||
| 12.05. | IceCure Medical Ltd Q1 Sales Increase | 1 | RTTNews | ||
| 12.05. | IceCure Medical: IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America | 527 | PR Newswire | Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared... ► Artikel lesen | |
| 10.05. | Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag | 33 | Seeking Alpha |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,482 | -0,52 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| LIFEWARD | 7,500 | +0,40 % | Lifeward Ltd.: Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth | Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support continued commercial... ► Artikel lesen | |
| IMUNON | 1,380 | 0,00 % | Imunon to host R&D day on Sept. 23 for ovarian cancer therapy | ||
| INSPIREMD | 0,780 | +5,41 % | InspireMD Inc.: InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing | MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced... ► Artikel lesen | |
| MYOMO | 1,360 | -1,88 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| GT BIOPHARMA | 0,300 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE- in multiple solid tumor types known to express B7-H3... ► Artikel lesen | |
| INOGEN | 4,660 | -0,85 % | Inogen (INGN) Cuts Guidance Even As Profitability Climbs | ||
| INTELLIGENT BIO SOLUTIONS | 2,330 | 0,00 % | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | ||
| GLUCOTRACK | 0,282 | 0,00 % | Glucotrack, Inc. Announces Reverse Stock Split | 1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026
RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack"... ► Artikel lesen | |
| LENSAR | 8,280 | -0,24 % | LENSAR, Inc.: LENSAR Reports First Quarter 2026 Results and Provides Business Update | 7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 10,570 | +2,13 % | Lexaria Bioscience Corp.: DehydraTECH-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 | Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation increased... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,640 | 0,00 % | Incannex Healthcare: Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X | NEW YORK and MELBOURNE, Australia, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative... ► Artikel lesen | |
| HEARTBEAM | 0,467 | 0,00 % | HeartBeam schließt Aktienverkaufsvereinbarung über 25 Millionen US-Dollar mit Titan Partners | ||
| MINIMED GROUP | 16,100 | -7,13 % | Top Wall Street Forecasters Revamp MiniMed Group Expectations Ahead Of Q1 Earnings | ||
| JIN MEDICAL INTERNATIONAL | 2,360 | +0,85 % | JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results | CHANGZHOU, China, Aug. 4, 2026 /PRNewswire/ -- JIN MEDICAL INTERNATIONAL LTD. (Nasdaq: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated... ► Artikel lesen |
Das Unternehmen ICECURE MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,285 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ICECURE MEDICAL LTD finden Sie auf Wallstreet Online.